H

Hanall Biopharma Co Ltd
KRX:009420

Watchlist Manager
Hanall Biopharma Co Ltd
KRX:009420
Watchlist
Price: 47 300 KRW 12.09% Market Closed
Market Cap: 2.5T KRW

Hanall Biopharma Co Ltd's latest stock split occurred on May 24, 2006

The company executed a 4981-for-4732 stock split, meaning that for every 4732 shares held, investors received 4981 new shares.

The adjusted shares began trading on May 24, 2006. This was Hanall Biopharma Co Ltd's 5th stock split, following the previous one in May 3, 2006.

Last Splits:
May 24, 2006
4981-for-4732
May 3, 2006
10-for-1
Apr 28, 2006
10-for-1
Oct 10, 1996
723-for-665
Jan 3, 1996
51-for-50
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After
Last Splits:
May 24, 2006
4981-for-4732
May 3, 2006
10-for-1
Apr 28, 2006
10-for-1
Oct 10, 1996
723-for-665
Jan 3, 1996
51-for-50

Hanall Biopharma Co Ltd
Stock Splits History

Hanall Biopharma Co Ltd Stock Splits Timeline
May 24, 2006
May 24, 2006
Split 4981-for-4732
x1.0526204564666
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After
May 3, 2006
May 3, 2006
Split 10-for-1
x10
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After
Apr 28, 2006
Apr 28, 2006
Split 10-for-1
x10
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After
Oct 10, 1996
Oct 10, 1996
Split 723-for-665
x1.0872180451128
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After
Jan 3, 1996
Jan 3, 1996
Split 51-for-50
x1.02
Pre-Split Price
N/A
Post-Split Price
6 710
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.46 8.46 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 7.8736 USD 7.93 7.93 USD
Load More

Hanall Biopharma Co Ltd
Glance View

Market Cap
2.4T KRW
Industry
Pharmaceuticals

Hanall Biopharma Co., Ltd., a Seoul-based pharmaceutical entity, has been navigating the competitive seas of the global health industry since 1973. Driven by a mission to address unmet medical needs, the company has positioned itself at the forefront of innovative drug development and biosimilars. Hanall's spotlight in recent years has been on its dedication to improving the lives of patients suffering from autoimmune and rare diseases. By focusing on cutting-edge solutions, the firm has garnered attention through its proprietary products and partnerships, such as its notable alliance with Harbour BioMed. This partnership has been pivotal in propelling their flagship drug candidates through the complex corridors of clinical trials and regulatory approvals. Central to Hanall Biopharma's business model is a dual strategy: developing novel therapeutics and capitalizing on biosimilar drugs. The company invests significantly in research and development, orchestrating a pipeline that balances groundbreaking therapies with the more predictable revenue streams of biosimilars. These biosimilars, essentially comparable versions of existing biologic drugs, allow Hanall to leverage lower development costs while addressing market demands for more affordable healthcare solutions. With revenues flowing from successful collaborations and sales of active pharmaceuticals, Hanall continues to chart a course through the diverse challenges of biopharmaceutical innovation and market competition.

Intrinsic Value
5 732.56 KRW
Overvaluation 88%
Intrinsic Value
Price
H
Back to Top